Form 4: Humana Director Karen Katz Boosts RSU Holdings

Humana Director Karen Katz reported an increase in her beneficial ownership of Restricted Stock Units through annual fees and dividend reinvestments.

Summary

• Karen Katz, a Director at Humana Inc., reported changes in her beneficial ownership of company securities.
• She directly owns 590 shares of Humana Common Stock.
• On January 2, 2026, she acquired 766 Restricted Stock Units (RSUs) as an annual director's fee. These RSUs are deferred and will convert to common stock upon her resignation.
• On December 31, 2025, she acquired an additional 49 RSUs through the reinvestment of a dividend payment, at a price of $258.8675 per unit. These are also deferred.
• Following these transactions, her beneficial ownership of RSUs related to annual fees increased to 3,627 units.
• Her beneficial ownership of RSUs from dividend reinvestment increased to 124 units.
• She also holds 535 RSUs from converted director's cash fees.
• All acquired RSUs are deferred until her resignation as a director, at which point they will be payable in Humana Inc. common stock on a 1-for-1 basis.

Sentiment

Score: 7

Explanation: The filing indicates routine insider transactions that align director interests with shareholders through equity compensation and dividend reinvestment, which is generally positive for corporate governance and investor confidence. No negative or highly unusual activity is reported.

Positives

• A director is increasing her stake in the company through RSU grants and dividend reinvestment, aligning her interests with shareholders.
• The deferral of stock units until resignation indicates a long-term commitment to the company's performance.

Future Outlook

The filing indicates that the acquired Restricted Stock Units are deferred until the director's resignation, aligning future payouts with long-term company performance.

Management Comments

• Annual Director's fee payable in stock units which have been deferred at the election of the Reporting Person until her resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis.
• Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until her resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis.
• Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until her resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis.

Industry Context

This Form 4 filing reflects standard executive compensation practices within the healthcare insurance industry, where directors often receive a portion of their compensation in equity to align their interests with long-term shareholder value. The deferral mechanism is a common corporate governance practice.

Comparison to Industry Standards

• The practice of compensating directors with Restricted Stock Units (RSUs) is a common standard across the S&P 500 and particularly prevalent in the healthcare sector, including peers like UnitedHealth Group (UNH) and Elevance Health (ELV).
• Deferring RSU payouts until resignation is a robust corporate governance practice, similar to policies seen at companies such as CVS Health (CVS) and Cigna (CI), encouraging long-term commitment and discouraging short-term decision-making.
• Dividend reinvestment into equity by directors is also a positive sign, demonstrating confidence in the company's future, a practice observed in many mature, dividend-paying companies.

Corporate Governance

Stakeholder Impact

• Shareholders: Positive, as director's interests are further aligned with long-term company performance through increased equity holdings and deferred compensation.

Next Steps

• The acquired Restricted Stock Units will be payable in Humana Inc. common stock on a 1-for-1 basis upon Karen Katz's resignation as a director.

Key Dates

Recommendation

This Form 4 filing reports routine insider transactions related to director compensation, including the acquisition of Restricted Stock Units through annual fees and dividend reinvestment. While these actions demonstrate a director's continued alignment with shareholder interests and confidence in the company's long-term prospects, they do not present new fundamental information that would warrant a change in an existing investment thesis. The transactions are expected and reflect standard corporate governance practices, thus supporting a 'hold' recommendation for investors already positioned in Humana.

Keywords

Humana Inc., HUM, Karen Katz, Director, SEC Form 4, Insider Trading, Restricted Stock Units, RSU, Beneficial Ownership, Equity Compensation, Dividend Reinvestment